Pfizer Filing Shows 70 Percent Decline in COVID Vaccine Revenue

Pfizer wrote in an SEC filing that its vaccine revenue is down 70 percent for 2023.

A health worker uses a needle and a vial of Pfizer-BioNTech COVID-19 vaccine to prepare a dose at a vaccination health center in a file photo. Justin Tallis/AFP via Getty Images

Vaccine-maker Pfizer Inc., in a filing to the U.S. Securities Exchange Commission, wrote that its COVID-19 vaccine revenue is down 70 percent in 2023.

“Declines largely driven by lower contracted deliveries and demand in international markets and lower U.S. government contracted deliveries, due to transition to new variant vaccines in most markets and the transition to traditional U.S. commercial market sales which began in September 2023,” the company wrote in the filing, which was drafted last week.